Generic Name and Formulations:
Ursodiol 250mg; tabs.
Indications for URSO:
Primary biliary cirrhosis.
Take with food. 13–15mg/kg per day in 2–4 divided doses.
Complete biliary obstruction.
Variceal bleeding, hepatic encephalopathy, ascites, and/or need for an urgent liver transplant: give appropriate specific treatment. Monitor liver function and bilirubin monthly for 3 months after starting therapy, then every 6 months thereafter; consider discontinuing if levels increase significantly with history of stable liver function. Monitor and maintain bile flow. Pregnancy (Cat.B). Nursing mothers.
Reduced absorption with bile acid sequestrants (eg, cholestyramine, colestipol), and aluminum-containing antacids. Estrogens, oral contraceptives, clofibrate, other lipid-lowering drugs may reduce effectiveness of ursodiol by increasing hepatic cholesterol secretion.
Abdominal discomfort or pain, alopecia, diarrhea, nausea, pruritus, rash, leukopenia, elevated creatinine or blood glucose, thrombocytopenia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline